Cargando…
Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET
Imaging biomarkers can be used to screen participants for Alzheimer's disease clinical trials. To test the predictive values in clinical progression of neuropathology change (amyloid‐PET) or brain metabolism as neurodegeneration biomarker ([18F]FDG‐PET), we evaluated data from N = 268 healthy c...
Autores principales: | Iaccarino, Leonardo, Sala, Arianna, Perani, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562030/ https://www.ncbi.nlm.nih.gov/pubmed/31211176 http://dx.doi.org/10.1002/acn3.782 |
Ejemplares similares
-
A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014) -
Erratum to “A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis”
por: Perani, Daniela, et al.
Publicado: (2014) -
The emerging role of PET imaging in dementia
por: Iaccarino, Leonardo, et al.
Publicado: (2017) -
Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification
por: Presotto, Luca, et al.
Publicado: (2018) -
PET Neuroimaging: Insights on Dystonia and Tourette Syndrome and Potential Applications
por: Alongi, Pierpaolo, et al.
Publicado: (2014)